Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Five Prime Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Five Prime Therapeutics Raises US$10 Million In Venture Financing 13
Partnerships 14
Five Prime Therapeutics Enters into Partnership with Roche 14
Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 15
Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 16
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 17
Five Prime Therapeutics Enters Into Research Agreement With Adimab 20
UCB Enters Into Research Agreement With Five Prime Therapeutics 21
Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 22
Licensing Agreements 23
UCB Enters into Licensing Agreement with Five Prime Therapeutics 23
Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24
Ablexis Enters into Licensing Agreement with Five Prime Therapeutics 25
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 26
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 27
Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 28
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 30
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 32
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 33
Equity Offering 35
Five Prime Therapeutics Plans to Raise up to USD250 Million in Public Offering of Shares 35
Five Prime Therapeutics Raises USD115 Million in Public offering of Shares 36
Five Prime Therapeutics Raises USD84.3 Million in Public Offering of Shares 38
Five Prime Therapeutics Completes Private Placement Of Shares For US$21 Million 40
Five Prime Therapeutics Completes Public Offering Of Shares For US$43 Million 41
Five Prime Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option Of IPO For US$71.8 Million 43
Five Prime Therapeutics Inc – Key Competitors 45
Five Prime Therapeutics Inc – Key Employees 46
Five Prime Therapeutics Inc – Locations And Subsidiaries 47
Head Office 47
Recent Developments 48
Financial Announcements 48
Nov 07, 2018: Five Prime Therapeutics announces third quarter 2018 financial results 48
Aug 08, 2018: Five Prime Therapeutics announces second quarter 2018 financial results 51
May 08, 2018: Five Prime Therapeutics Reports First Quarter 2018 Financial Results 53
Feb 27, 2018: Five Prime Announces Fourth Quarter and Full Year 2017 Financial Results 55
Nov 06, 2017: Five Prime Announces Third Quarter 2017 Results and Provides Business Update 59
Aug 08, 2017: Five Prime Announces Second Quarter 2017 Results and Provides Business Update 61
May 04, 2017: Five Prime Announces First Quarter 2017 Results and Provides Business Update 65
Feb 23, 2017: Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results 69
Corporate Communications 72
Nov 05, 2018: Five Prime Therapeutics announces David V. Smith Will Join as Chief Financial Officer 72
May 15, 2018: Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer 73
Mar 13, 2018: Five Prime Therapeutics Announces Executive Change 74
Oct 23, 2017: Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018 75
Aug 17, 2017: Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research 76
Jun 21, 2017: Five Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018 77
May 15, 2017: Five Prime Welcomes Garry Nicholson to Board of Directors 78
Mar 20, 2017: Five Prime Therapeutics Announces Executive Changes 79
Product News 80
04/20/2017: Five Prime to Present Clinical Data on FPA144 at 2017 ASCO Annual Meeting 80
Clinical Trials 81
Jan 02, 2018: Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer 81
Nov 10, 2017: Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting 82
Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155 83
Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 84
Jul 17, 2017: Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development 85
Jun 03, 2017: Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting 86
Other Significant Developments 88
May 29, 2018: Five Prime Therapeutics Walks to End Pancreatic Cancer at PurpleStride San Francisco 2018 88
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Five Prime Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Five Prime Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Five Prime Therapeutics Raises US$10 Million In Venture Financing 13
Five Prime Therapeutics Enters into Partnership with Roche 14
Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 15
Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 16
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 17
Five Prime Therapeutics Enters Into Research Agreement With Adimab 20
UCB Enters Into Research Agreement With Five Prime Therapeutics 21
Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 22
UCB Enters into Licensing Agreement with Five Prime Therapeutics 23
Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24
Ablexis Enters into Licensing Agreement with Five Prime Therapeutics 25
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 26
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 27
Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 28
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 30
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 32
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 33
Five Prime Therapeutics Plans to Raise up to USD250 Million in Public Offering of Shares 35
Five Prime Therapeutics Raises USD115 Million in Public offering of Shares 36
Five Prime Therapeutics Raises USD84.3 Million in Public Offering of Shares 38
Five Prime Therapeutics Completes Private Placement Of Shares For US$21 Million 40
Five Prime Therapeutics Completes Public Offering Of Shares For US$43 Million 41
Five Prime Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option Of IPO For US$71.8 Million 43
Five Prime Therapeutics Inc, Key Competitors 45
Five Prime Therapeutics Inc, Key Employees 46
List of Figures
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Five Prime Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10